Picture EBD Group Bio-Europe Spring 2024 Barcelona 650x100px
Organisation › Details

Owlstone Medical Ltd.

Owlstone Medical has developed a unique breathalyzer for disease. The company’s vision is to become the global leader in non-invasive breath tests for early disease detection and precision medicine across cancer, inflammatory disease and infectious disease with the aim of saving 100,000 lives and $1.5 billion in healthcare costs. Owlstone Medical’s Breath Biopsy® platform is creating a new industry category, based on the routine detection and analysis of volatile organic compound (VOC) biomarkers in breath, which has the potential to revolutionize healthcare. The award winning ReCIVA Breath Sampler is the first standardized breath collection device designed to capture the VOC biomarkers present in breath, which are then analyzed using Owlstone Medical’s Breath Biopsy services and products. Owlstone Medical is developing breath tests for the early detection of lung and colorectal cancer. These are two of the most common cancer killers worldwide and represent multibillion dollar market opportunities. The company has an active clinical diagnostics/screening pipeline including the world’s largest breath-based clinical trials. The Breath Biopsy platform is also being deployed in the PAN cancer trial, a collaboration with Cancer Research UK studying the early detection of eight different cancer types in breath. The company also sees a significant role for Breath Biopsy in precision medicine, where it can provide dynamic information about a patient’s disease activity and identify patients most likely to respond to a particular therapy. Breath Biopsy aims to ensure that the right therapy is given to the right patient at the right time, helping to improve patient outcomes and reduce healthcare costs. Owlstone Medical’s Breath Biopsy clinical laboratory is a unique, revenue generating capability that allows pharmaceutical, clinical and academic partners worldwide to explore breath-based biomarkers to optimize their own precision medicine activities. The commercialization of Breath Biopsy precision medicine companion diagnostics through pharmaceutical partners is expected to provide Owlstone Medical with a significant royalty stream as breath-based precision medicine becomes a reality. Owlstone Medical was spun out of Owlstone Inc. in 2016 to develop and commercialize medical applications of its proprietary microchip chemical sensing technology, Field Asymmetric Ion Mobility Spectrometry (FAIMS), which is sold in the military and industrial sectors globally. The company has raised a total of $38.5 million in equity financing, and is backed by technology investor Horizons Ventures, and Aviva, a leading healthcare insurer. Owlstone Medical is headquartered in Cambridge, UK. *


Period Start 2016-01-01 established (s-off)
  Group Owlstone (Group)
  Predecessor Owlstone Inc.
Products Industry FAIMS technology
  Industry 2 Breathalyzer
Persons Person Boyle, Billy (Owlstone 201606 CEO + Co-Founder of Owlstone Medical Ltd)
  Person 2 Toumazou, Christofer (Chris) (DNA Electronics 201011 CEO)
Region Region Cambridge, Cambridgeshire
  Country United Kingdom (GB)
  Street Milton Road
Cambridge Sciencde Park, 162
  City CB4 0GH Cambridge, Cambridgeshire
  Tel +44-1223-428200
    Address record changed: 2024-01-05
Basic data Employees n. a.
    * Document for »About Section«: Owlstone Medical Ltd.. (3/5/18). "Press Release: Owlstone Medical Raises $15 Million USD (£11 Million GBP) with Horizons Ventures and Aviva". Cambridge.
Record changed: 2024-01-20


Picture Consultech GmbH Secure Funding with RnD Grants 650x200px

More documents for Owlstone (Group)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture Kenes Exhibitions Biomed Israel 2024 Tel Aviv 650x300px

» top